Ongoing launch of CASGEVY® continues to gain momentum- -2025 is poised to be a catalyst-rich year with key updates across ...

If we assume all patients who began treatment with Casgevy last year progress to the administration stage, CRISPR and Vertex ...

Analyst Gil Blum from Needham maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) and keeping the price target at ...

Scribe announced its initial research collaboration with Sanofi for CRISPR-based cell therapies to address oncology ...

The "CRISPR-based Gene Editing Market by Product & Service, by Application, by End-User, and By Region" report has been added ...

Financial writer recommends buying Intellia Therapeutics, Inc. stock as it restructures, focusing on late-stage programs for ...

Intellia expects to incur charges of $8m associated with the reorganisation, which will likely be incurred in Q1 2025.

Biotech stocks are poised for an exciting 2025 as experts watch for new weight-loss drugs, AI's impact and Trump's second ...

J.P. Morgan analyst Brian Cheng has maintained their bullish stance on NTLA stock, giving a Buy rating today.Stay Ahead of the Market:Discover ...

The biotech plans to use the funding to advance clinical testing of an epigenetic silencing therapy it hopes could treat ...

Shortly after arriving in Ottawa with her two young children, following her husband's appointment as Cameroon's High Commissioner (Ambassador) to Canada, Mercy Azoh-Mbi complained of fatigue, fever, a ...

A study published in Foresight demonstrates that Kognitic's neural network model significantly outperforms traditional methods in predicting primary completion dates (PCD) for clinical trials, ...